Koate-DVI 500 IU Injection 5 ml

Koate-DVI 500 IU Injection 5 ml is used in the treatment and prevention of bleeding in patients with haemophilia A. Hemophilia A is a genetic bleeding disorder caused by a deficiency or absence of clotting factor VIII that impairs the blood’s ability to clot. It leads to prolonged bleeding episodes, often following injuries or surgeries, and can cause spontaneous internal bleeding.

Koate-DVI 500 IU Injection 5 ml contains Dried human antihemophilic factor VIII fraction, which works by replacing the missing or deficient clotting factor VIII in individuals with haemophilia A. This helps restore the blood's clotting ability, preventing or treating bleeding episodes. As a result, it helps in managing bleeding and reducing the risk of spontaneous bleeds or bleeding during physical activities.

The dose and duration of treatment with Koate-DVI 500 IU Injection 5 ml may vary based on your medical condition being treated. The common side effects of Koate-DVI 500 IU Injection 5 ml include chills, rash, flushing (sudden reddening of the skin), nausea and dizziness. Most of these side effects may resolve gradually over time on their own. However, consult the doctor if any of these symptoms persist or worsen.

Inform your doctor if you are pregnant or planning to become pregnant or breastfeeding while treatment with Koate-DVI 500 IU Injection 5 ml to evaluate the potential risks and benefits. Koate-DVI 500 IU Injection 5 ml is safe for children if prescribed by the doctor. Koate-DVI 500 IU Injection 5 ml may cause dizziness; therefore, avoid driving or operating heavy machinery unless fully alert. Inform your doctor about all the medicines you are taking and about your pre-existing health conditions to rule out any unpleasant side effects/interactions.

Koate-DVI 500 IU Injection 5 ml is used to treat and prevent bleeding in patients with hemophilia A, a genetic disorder caused by a deficiency of factor VIII. The detailed uses of Koate-DVI 500 IU Injection 5 ml are as follows:

• Treats active bleeding episodes:Koate-DVI 500 IU Injection 5 ml helps control and stop bleeding by replacing the missing clotting factor VIII.
• Prevents future bleeding:Koate-DVI 500 IU Injection 5 ml is used regularly to reduce the frequency of bleeding episodes in patients with hemophilia A.
• Supports bleeding control during surgeries or dental procedures:Koate-DVI 500 IU Injection 5 ml ensures proper clot formation to prevent excessive bleeding in hemophilia A patients undergoing operations.
• Manages bleeding in patients with factor VIII inhibitors:Koate-DVI 500 IU Injection 5 ml aids in promoting clotting even in individuals who have developed resistance to standard factor VIII therapy.

• Follow your doctor's instructions on the dosage and timing of this medication.
• Koate-DVI 500 IU Injection 5 ml will be administered by the doctor or nurse in a healthcare setting.
• Do not self-administer.

Koate-DVI 500 IU Injection 5 ml belongs to the group of medications called hematologic agents. It contains dried human antihaemophilic factor VIII fraction, which replicates the function of factor VIII, a crucial protein for blood clotting. It connects activated factor IX and factor X, promoting effective clot formation in individuals with hemophilia A. This process helps prevent and minimize bleeding episodes, including in patients with factor VIII inhibitors. It is used for the treatment and prevention of bleeding in patients with haemophilia A, a genetic bleeding disorder caused by a deficiency of factor VIII.

Koate-DVI 500 IU Injection 5 ml may cause severe allergic reactions in some individuals, including anaphylaxis, which requires immediate discontinuation of treatment. Notify your doctor if you experience any symptoms, like difficulty breathing or dizziness. Inform your doctor if you have any risk factors, as thromboembolic events, including blood clots like pulmonary embolism, can occur, particularly in patients with immobility, surgery, or obesity. Since the product is derived from human plasma, there is a potential risk of transmitting infectious agents, even with viral inactivation and screening precautions. Therefore, Inform your doctor if you experience any symptoms or signs of infection. It is essential to regularly monitor your Factor VIII levels, especially during active bleeding or treatment, to ensure you are receiving the correct dosage.